纤维蛋白
因素七
医学
因子IX
内科学
凝结
化学
药理学
免疫学
作者
Eisuke Takami,Kazuhito Hashimoto,Ryoichi Kitano,Kazuhiro Nishikawa,Takashi Fuchigami,Hirotoshi Nakano
标识
DOI:10.1016/j.thromres.2023.01.020
摘要
Replacing deficient factor (F) VIII or FIX is the most common treatment strategy for congenital hemophilia; however, repeated infusions can promote the formation of FVIII or FIX inhibitors. Importantly, the appearance of these inhibitors significantly reduces the hemostatic effect of regular FVIII or FIX replacement [1]. Recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) are used for hemostatic management in patients having hemophilia with inhibitors (PHwI).
科研通智能强力驱动
Strongly Powered by AbleSci AI